The latest news and updates from Entrada Therapeutics

Filter By:

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

BOSTON, Mass., Dec. 18, 2018 – Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced it has raised $59 million in a Series A financing.

Read more
December 18, 2018